Keyword: Jardiance

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics look particularly strong.

Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.

ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Lilly and BI unveiled new Jardiance data that could line them up to compete with Johnson & Johnson's Invokana in a new patient group.

AstraZeneca is touting SGLT2 med Farxiga’s cardiovascular outcomes win as a game changer for the market. Turns out the FDA likes those results, too.

Heart benefits offered by Novo Nordisk's oral version of its hit drug for Type 2 diabetes, Ozempic, won't justify its price, ICER said.

Now that AstraZeneca has scored its Farxiga outcomes data, it's beefing up its sales team to prepare for an expanded FDA approval.